logo

Enter Symbol

INVITROGEN(NSDQ:IVGN)
Invitrogen Corporation provides products and services that support academic and government research institutions and pharmaceutical and biotech companies worldwide in their efforts to improve the human condition. The company provides essential life science technologies for disease research, drug discovery, and commercial bioproduction. Invitrogen''s own research and development efforts are focused on breakthrough innovation in all major areas of biological discovery including functional genomics, proteomics, bioinformatics and cell biology placing Invitrogen''s products in nearly every major laboratory in the world.
# Employees: 4300
Address: 1600 Faraday Avenue,Carlsbad,CA,USA
Phone: 760 603-7200
Fax: 760 602-6500
Website: www.invitrogen.com
Email: ir@invitrogen.com
Sector: Medical
Industry: MED PRODUCTS
Executive Officers
Gregory T. Lucier (Chmn.; C.E.O.; Dir.)
Claude D. Benchimol Ph.D (Sr. V.P.; Research & Development)
John A. Cottingham (Sr. V.P. Gen. Counl. & Sec.)
David F. Hoffmeister (Sr. V.P.; C.F.O.)
John D. Thompson (Sr. V.P.; Corp. Develop.,)
Dividend
Ex-Dividend Date: N/A
Annual Dividend: N/A
Current Dividend Yield: N/A
Dividend Paid (3 months): N/A
Indicated Dividend: N/A
Earnings
Last Earnings Date: 9/30/2008
Next Earnings Date(Expected): 2/10/2009
Mean EPS (Next Qtr): $0.58
Mean EPS (Year): $2.58
Mean Estimate(Long Term): $12.80
P/E Ratio(Based on EPS estimate): 8.610
Number of Estimates: 12
Shares Performance
Period IVGN Compare to S&P
YTD -52.40 % -12.64 %
4 Weeks -16.49 % -8.48 %
12 Weeks -47.65 % -16.05 %
Shares Information
Analyst Coverage: Y
Avg Volume: 3943548
Shares Outstanding: 92M
Market Cap: $2.05B
52 Week High: $49.22
52 Week Low: $21.10
P/E Ratio: 8.730
PEG Ratio: 0.670
Split: On 5/28/2008 IVGN split by factor of 2.000
Earnings Performance
EPS Growth in Last Quarter: -7.35 %
EPS Growth in Last Year: 23.53 %
Sales Growth in Last Quarter: -1.66 %
Sales Growth in Last Quarter: 14.84 %
Financials
Qtr Book Value: $1.11
Cash Flow/Share: $6.20
Change in Payout Ratio: 0.000
Price/Sales: 1.450
Fundamental data is provided by Zacks Investment Research, market data is provided by AlphaTrade. , and Commentary and Press Releases provided by Quotemedia